secwatch.observer — SEC 8-K summary
======================================

Issuer:     AIM ImmunoTech Inc. (AIM)
CIK:        0000946644
Form:       8-K
Filed at:   2025-04-04T23:59:59+00:00
Accession:  0001641172-25-002702
Event type: other_material
Sentiment:  neutral
Materiality: 0.55
Item codes: 1.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

AIM ImmunoTech enters ATM offering agreement for up to $3M common stock
-----------------------------------------------------------------------

- Entered Equity Distribution Agreement with Maxim Group LLC for at-the-market offering of up to $3M common stock.
- Currently limited to selling $663,329 due to Form S-3 General Instruction I.B.6; registration statement not yet effective.
- Maxim receives 3.0% commission on gross proceeds; expense reimbursement up to $50,000 initial, $5,000 quarterly.
- Net proceeds to be used for working capital and general corporate purposes.
- Agreement may be terminated by either party on 15 days' notice or after 24 months.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/946644/000164117225002702/0001641172-25-002702-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/946644/000164117225002702/form8-k.htm
  HTML page:      https://secwatch.observer/filing/0001641172-25-002702

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer